FRM
KYMR icon

Fox Run Management’s Kymera Therapeutics KYMR Stock Holding History

Fox Run Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,120
Closed -$332K – 966
2024
Q2 		$332K Buy
+11,120
New +$385K 0.06% 534
2024
Q1 		– Sell
-8,135
Closed -$207K – 940
2023
Q4 		$207K Buy
+8,135
New +$145K 0.05% 623

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fox Run Management's KYMR Position: Q3 2024 in Review

Fox Run Management sold out of Kymera Therapeutics (KYMR) in Q3 2024, closing a stake of 11,120 shares — an estimated $332K sold.

Fox Run Management first reported a position in KYMR in Q4 2023 and held it in 2 quarters. The position peaked at $332K in Q2 2024. 176 funds tracked by Wall St. Rank hold KYMR as of Q3 2024.

  • Fox Run Management reported no remaining Kymera Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Fox Run Management sold 11,120 Kymera Therapeutics shares in Q3 2024, an estimated $332K.
  • Fox Run Management first reported a position in Kymera Therapeutics in Q4 2023 and held it in 2 quarters.
  • Fox Run Management's Kymera Therapeutics position peaked at $332K in Q2 2024.
  • 176 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2024.

Based on Fox Run Management's 13F filing for Q3 2024, filed 12 Nov 2024.